Zhengbin Zhu1,2, Jinzhou Zhu1,2, Run Du1,2, Haotian Zhang1, Jinwei Ni1, Weiwei Quan1, Jian Hu1, Fenghua Ding1,2, Zhenkun Yang1, Ruiyan Zhang3,4. 1. Department of Cardiology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. 2. Cardiovascular Research Institution, Shanghai Jiao Tong University School of Medicine, Shanghai, China. 3. Department of Cardiology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. drzhangruiyan@sina.com. 4. Cardiovascular Research Institution, Shanghai Jiao Tong University School of Medicine, Shanghai, China. drzhangruiyan@sina.com.
Abstract
BACKGROUND: Diabetes mellitus (DM) plays an important role in restenosis and late in-stent thrombosis (ST). The current study using optical coherence tomography (OCT) aims to compare target lesion neointima in patients with or without diabetes after zotarolimus-eluting stent (ZES) treatment. METHODS: OCT images of 90,212 struts and quantitative coronary angiography (QCA) in 62 patients (32 with DM and 30 without DM) with 69 de novo coronary lesions (34 DM and 35 non-DM) both after ZES implantation and 12 ± 1 month angiographic follow-up were recorded. Patient characteristics, lesion characteristics, clinical outcomes, and OCT findings including neointimal thickness, coverage, malapposition, and intimal morphology were analyzed. RESULTS: Baseline patient characteristics and lesion characteristics data were similar between the two groups. Higher neointimal thickness (0.14 ± 0.09 mm vs. 0.09 ± 0.04 mm, p = 0.021), more neovascularization (3.03 ± 6.24 vs. 0.52 ± 1.87, p = 0.017) and higher incidence of layered signal pattern (12.19 ± 19.91% vs. 4.28 ± 9.02%, p = 0.049) were observed in diabetic lesions comparing with non-diabetic lesions. No differences were found in malapposition, uncovered percentage, and thrombus between the two groups (all p > 0.05). Occurrence of clinical adverse events was also similar during the follow-up period (p > 0.05). CONCLUSION: Although more neointimal proliferation and more neovascularization were found in diabetic coronary lesions when compared with non-diabetic lesions, treatment with ZES showed similar stent malapposition rate at 1-year follow-up. The data indicated that ZES treatment could possibly be effective in treating diabetic coronary lesions. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT01747356.
BACKGROUND: Diabetes mellitus (DM) plays an important role in restenosis and late in-stent thrombosis (ST). The current study using optical coherence tomography (OCT) aims to compare target lesion neointima in patients with or without diabetes after zotarolimus-eluting stent (ZES) treatment. METHODS: OCT images of 90,212 struts and quantitative coronary angiography (QCA) in 62 patients (32 with DM and 30 without DM) with 69 de novo coronary lesions (34 DM and 35 non-DM) both after ZES implantation and 12 ± 1 month angiographic follow-up were recorded. Patient characteristics, lesion characteristics, clinical outcomes, and OCT findings including neointimal thickness, coverage, malapposition, and intimal morphology were analyzed. RESULTS: Baseline patient characteristics and lesion characteristics data were similar between the two groups. Higher neointimal thickness (0.14 ± 0.09 mm vs. 0.09 ± 0.04 mm, p = 0.021), more neovascularization (3.03 ± 6.24 vs. 0.52 ± 1.87, p = 0.017) and higher incidence of layered signal pattern (12.19 ± 19.91% vs. 4.28 ± 9.02%, p = 0.049) were observed in diabetic lesions comparing with non-diabetic lesions. No differences were found in malapposition, uncovered percentage, and thrombus between the two groups (all p > 0.05). Occurrence of clinical adverse events was also similar during the follow-up period (p > 0.05). CONCLUSION: Although more neointimal proliferation and more neovascularization were found in diabetic coronary lesions when compared with non-diabetic lesions, treatment with ZES showed similar stent malapposition rate at 1-year follow-up. The data indicated that ZES treatment could possibly be effective in treating diabetic coronary lesions. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT01747356.
Authors: Tullio Palmerini; Umberto Benedetto; Giuseppe Biondi-Zoccai; Diego Della Riva; Letizia Bacchi-Reggiani; Pieter C Smits; Georgios J Vlachojannis; Lisette Okkels Jensen; Evald H Christiansen; Klára Berencsi; Marco Valgimigli; Carlotta Orlandi; Mario Petrou; Claudio Rapezzi; Gregg W Stone Journal: J Am Coll Cardiol Date: 2015-06-16 Impact factor: 24.094
Authors: Gregg W Stone; Stephen G Ellis; Louis Cannon; J Tift Mann; Joel D Greenberg; Douglas Spriggs; Charles D O'Shaughnessy; Samuel DeMaio; Patrick Hall; Jeffrey J Popma; Joerg Koglin; Mary E Russell Journal: JAMA Date: 2005-09-14 Impact factor: 56.272
Authors: Alan C Yeung; Martin B Leon; Ash Jain; Thaddeus R Tolleson; Douglas J Spriggs; Brent T Mc Laurin; Jeffrey J Popma; Peter J Fitzgerald; Donald E Cutlip; Joseph M Massaro; Laura Mauri Journal: J Am Coll Cardiol Date: 2011-04-04 Impact factor: 24.094
Authors: Manel Sabate; Angel Cequier; Andrés Iñiguez; Antonio Serra; Rosana Hernandez-Antolin; Vicente Mainar; Marco Valgimigli; Maurizio Tespili; Pieter den Heijer; Armando Bethencourt; Nicolás Vazquez; Joan Antoni Gómez-Hospital; José Antonio Baz; Victoria Martin-Yuste; Robert-Jan van Geuns; Fernando Alfonso; Pascual Bordes; Matteo Tebaldi; Monica Masotti; Antonio Silvestro; Bianca Backx; Salvatore Brugaletta; Gerrit Anne van Es; Patrick W Serruys Journal: Lancet Date: 2012-09-03 Impact factor: 79.321
Authors: Eliano P Navarese; Kenneth Tandjung; Bimmer Claessen; Felicita Andreotti; Mariusz Kowalewski; David E Kandzari; Dean J Kereiakes; Ron Waksman; Laura Mauri; Ian T Meredith; Aloke V Finn; Hyo-Soo Kim; Jacek Kubica; Harry Suryapranata; Toni Mustahsani Aprami; Giuseppe Di Pasquale; Clemens von Birgelen; Elvin Kedhi Journal: BMJ Date: 2013-11-06
Authors: Run Du; Rui Yan Zhang; Lin Lu; Ying Shen; Li Jin Pu; Zheng Bin Zhu; Qi Zhang; Jian Hu; Zhen Kun Yang; Feng Hua Ding; Jian Sheng Zhang; Wei Feng Shen Journal: Cardiovasc Diabetol Date: 2018-11-27 Impact factor: 9.951